Analysts Set Verve Therapeutics, Inc. (NASDAQ:VERV) PT at $14.57

Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) has been assigned an average recommendation of "Hold" from the nine brokerages that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $14.57.

Several research firms have commented on VERV. Jefferies Financial Group downgraded shares of Verve Therapeutics from a "buy" rating to a "hold" rating and dropped their price objective for the company from $28.00 to $11.00 in a report on Wednesday, June 18th. HC Wainwright downgraded shares of Verve Therapeutics from a "buy" rating to a "neutral" rating and set a $13.50 price objective for the company. in a report on Wednesday, June 18th. Guggenheim increased their price objective on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a report on Tuesday, April 15th. William Blair downgraded shares of Verve Therapeutics from a "strong-buy" rating to a "market perform" rating in a report on Tuesday, June 17th. Finally, Cantor Fitzgerald raised shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, April 15th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. KFG Wealth Management LLC purchased a new position in Verve Therapeutics in the first quarter worth about $46,000. IFP Advisors Inc boosted its position in shares of Verve Therapeutics by 823,700.0% during the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after buying an additional 8,237 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Verve Therapeutics during the first quarter valued at approximately $47,000. E Fund Management Co. Ltd. purchased a new position in shares of Verve Therapeutics during the first quarter valued at approximately $48,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Verve Therapeutics during the fourth quarter valued at approximately $50,000. Hedge funds and other institutional investors own 97.11% of the company's stock.

Verve Therapeutics Stock Up 0.1%

VERV stock traded up $0.02 during mid-day trading on Thursday, hitting $11.23. The company had a trading volume of 1,140,860 shares, compared to its average volume of 2,453,494. The company has a 50-day moving average price of $6.74 and a 200 day moving average price of $6.28. Verve Therapeutics has a 12-month low of $2.86 and a 12-month high of $11.41. The company has a market capitalization of $1.00 billion, a price-to-earnings ratio of -5.32 and a beta of 2.23.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 303.64% and a negative return on equity of 35.81%. The business had revenue of $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. As a group, analysts expect that Verve Therapeutics will post -2.49 EPS for the current year.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.